ImmunoCellular Therapeutics, Ltd.: 10-Q filed 2013-05-10

Name: ImmunoCellular Therapeutics, Ltd.: 10-Q filed 2013-05-10
Creator: ImmunoCellular Therapeutics, Ltd.
License: https://creativecommons.org/licenses/by/4.0/

What ImmunoCellular Therapeutics, Ltd. reported in its quarterly report filed 2013-05-10 (fiscal Q1 2013): 28 published measures, 92 facts as tagged in accession 0000950123-13-003511.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-05-10
Fiscal period: fiscal Q1 2013
Accession: 0000950123-13-003511 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ImmunoCellular Therapeutics, Ltd. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-03-31	25,070,664	USD
At 2012-12-31	27,019,201	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2013-03-31	18,428,214	USD
At 2012-12-31	23,068,014	USD
At 2011-12-31	3,232,060	USD
At 2010-12-31	2,335,830	USD
At 2009-12-31	1,096,995	USD
At 2008-12-31	2,940,336	USD
At 2007-12-31	4,997,709	USD
At 2006-12-31	189,662	USD
At 2005-12-31	20,262	USD
At 2004-12-31	-11,494	USD
At 2004-02-24	97	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-03-31	24,104,258	USD
At 2012-12-31	26,216,668	USD
At 2012-03-31	13,555,909	USD
At 2011-12-31	6,653,168	USD
At 2004-02-24	0	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-4,973,791	USD	90
2004-02-25 to 2013-03-31	-46,050,121	USD	3323
2012-01-01 to 2012-12-31	-14,495,139	USD	366
2012-01-01 to 2012-03-31	-7,889,435	USD	91
2011-01-01 to 2011-12-31	-5,719,903	USD	365
2010-01-01 to 2010-12-31	-6,150,142	USD	365
2009-01-01 to 2009-12-31	-2,626,205	USD	365
2008-01-01 to 2008-12-31	-3,059,730	USD	366
2007-01-01 to 2007-12-31	-3,614,753	USD	365
2006-01-01 to 2006-12-31	-5,152,713	USD	365
2005-01-01 to 2005-12-31	-246,004	USD	365
2004-02-25 to 2004-12-31	-11,741	USD	311

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-2,207,273	USD	90
2004-02-25 to 2013-03-31	-30,751,247	USD	3323
2012-01-01 to 2012-03-31	-3,578,566	USD	91

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	0	USD	90
2004-02-25 to 2013-03-31	155,692	USD	3323
2012-01-01 to 2012-03-31	5,668	USD	91

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	0	USD	90
2004-02-25 to 2013-03-31	300,000	USD	3323
2012-01-01 to 2012-03-31	0	USD	91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	94,863	USD	90
2004-02-25 to 2013-03-31	55,036,197	USD	3323
2012-01-01 to 2012-03-31	10,486,975	USD	91

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	0	USD	90
2004-02-25 to 2013-03-31	-180,692	USD	3323
2012-01-01 to 2012-03-31	-5,668	USD	91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2013-03-31	-48,142,621	USD
At 2012-12-31	-43,168,830	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2013-01-01 to 2013-03-31	USD	90
2004-02-25 to 2013-03-31	USD	3323
2012-01-01 to 2012-03-31	USD	91

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2013-03-31	61,629	USD
At 2012-12-31	76,289	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	164,128	USD	90
2004-02-25 to 2013-03-31	8,817,984	USD	3323
2012-01-01 to 2012-03-31	245,107	USD	91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-2,348,656	USD	90
2004-02-25 to 2013-03-31	-41,709,528	USD	3323
2012-01-01 to 2012-03-31	-3,049,441	USD	91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-03-31	24,922,300	USD
At 2012-12-31	26,931,176	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-03-31	1,157,888	USD
At 2012-12-31	1,098,307	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-03-31	705,898	USD
At 2012-12-31	732,851	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	1,415,261	USD	90
2004-02-25 to 2013-03-31	19,675,374	USD	3323
2012-01-01 to 2012-03-31	1,998,536	USD	91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-03-31	51,500,996	shares
At 2012-12-31	51,500,996	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-03-31	66,565,668	USD
At 2012-12-31	66,231,694	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2013-03-31	141,001	USD
At 2012-12-31	151,573	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2013-03-31	-79,372	USD
At 2012-12-31	-75,284	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2013-03-31	362,292	USD
At 2012-12-31	56,111	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-4,973,791	USD	90
2004-02-25 to 2013-03-31	-48,142,621	USD	3323
2012-01-01 to 2012-03-31	-7,889,435	USD	91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	769,267	USD	90
2004-02-25 to 2013-03-31	13,454,014	USD	3323
2012-01-01 to 2012-03-31	805,798	USD	91

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	10,842	USD	90
2004-02-25 to 2013-03-31	86,127	USD	3323
2012-01-01 to 2012-03-31	11,444	USD	91

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	10,842	USD	90
2004-02-25 to 2013-03-31	86,127	USD	3323
2012-01-01 to 2012-03-31	11,444	USD	91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-26,953	USD	90
2004-02-25 to 2013-03-31	705,548	USD	3323
2012-01-01 to 2012-03-31	-430,720	USD	91

Inspect the source

Entity: ImmunoCellular Therapeutics, Ltd. / CIK 0000822411
Captured: 2026-09-23 02:41 UTC
SEC response SHA-256: 0eba79ec53d6fb769bdb10da640228441bb5660977a2ac000a6d3fe9f3678be8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000822411.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))